TXNIP and head and neck squamous cell carcinoma: As expected, treatment with pevonedistat resulted in a dose-dependent reduction of TXNIP protein expression in RPTECs (Fig. 3F) and increased TXNIP protein expression in both HNSCC cell lines (Fig. 3G).